

# Index

## PHARMACOLOGICAL REVIEWS\*

### Volume 25

1973

- O-Acetates, formation, 30  
Acetylation, gastrointestinal microorganisms, 499  
Acetylcholine action mechanism, 122  
Acetylcholine infusion  
atrium, effects on, 131  
ventricle, effects on, 135  
Adenosine  
effects on  
cyclic AMP accumulation, 81  
lipolysis, 81  
Adenosine monophosphate, cyclic  
adenosine effects on accumulation, 81  
cyclic carboxylic acids, effect, 86  
dihydroergotamine effect, 84  
drugs affecting action, 83  
effect of aspirin-like drugs, 87  
imidazoles effect on, 85  
lipolytic agents as stimulators, 79  
myocardial, regulation of, 126  
nucleoside inhibitors, 91  
oxidative metabolism, inhibitors and uncouplers, 89  
prostaglandins, effect, 87  
tolbutamide effects, 95  
valinomycin effects on accumulation, 81  
Adenosine triphosphatase  
activity in fat cells, 95  
tolbutamide effects, 95  
Adenylate cyclase, catecholamine activation, 77, 78  
Adipose tissue  
drug action, 67  
hormone action, 67  
Adrenaline action on splenic smooth muscle, 384, 386  
*alpha*-Adrenergic antagonists, inhibition, 76  
*beta*-Adrenergic antagonists  
inhibition, 75  
structures, 76  
*beta*-Adrenergic blockers, antagonists of catecholamine activation of adenylate cyclase, 78  
Adrenoceptor blocking drugs, actions on spleen, 393  
Alcohols, reduction by gastrointestinal microorganisms, 496  
Aldehydes, reduction by gastrointestinal microorganisms, 496  
N-Alkyl compounds, dealkylation, 477  
O-Alkyl compounds, dealkylation, 475  
Alkyl derivatives, dealkylation, 478  
Amides, hydrolysis, 463  
Aminoazo dyes, N-hydroxylation, 17  
Amitriptyline, effects on lipolysis, 97  
Amphetamine  
effects on  
lipolysis, 98  
splenic smooth muscle, 392  
Amytal, effect on lipase activity, 89  
Angiotensin  
administration into cerebrospinal fluid, 423  
adrenergic effect on CNS, 441  
*in vitro* effects, 442  
*in vivo* effects, 443  
brain, presence in, 419  
cardiovascular effects, proposed sites, 423  
central effects in man, 444  
cerebrospinal fluid, effects of administration (table), 429  
cholinergic effects on CNS, 441  
cranial circulation, effects of infusion (table), 424  
dipsogenic effects, 434  
effects on  
baroreceptor reflexes, 433  
central nervous system, 415  
cranial circulation, 422  
endogenous brain norepinephrine, 442  
hydration, 434  
significance, 439  
splenic smooth muscle, 401  
hypothalamus injections, 432  
influence on sympathetic nerve activity, 433  
isolated perfused head studies, 421  
macromolecular effects on CNS, 441, 443  
medulla injections, 432  
midbrain injection, 423  
peripherally administered, 419  
pituitary effects, 438

\* The subject index for the "New York Heart Association Symposium on Immunopharmacology" is found in *Pharmacological Reviews* 25; 157-371 (June), 1973. The author index for the June issue is included in the index presented here.

- Angiotensin II  
 cardiovascular effects, 421  
 effects of pharmacologic antagonists on drinking (table), 436  
 intravascular administration, 421
- Angiotensin activity  
 general comments, 415  
 methodological considerations, 416
- Angiotensin-CNS field, highlights (table), 417
- Antimycin A, effect on lipolytic activity, 89
- Archer, J. A. *See* Gorden *et al.*, 179
- Aromatization, gastrointestinal microorganisms, 497
- Arsonic acids, reduction by gastrointestinal microorganisms, 497
- Arylhydroxylamines, reactions, 4
- Aspirin-like drugs  
 effect on  
 cyclic AMP, 87  
 lipolysis, 87
- Atrium  
 ACh infusion effects, 131  
 vagal stimulation effects, 130
- Autonomic neurotransmitters, interaction, 129
- Azo groups, reduction by gastrointestinal microorganisms, 492
- Bacillus subtilis*, N-hydroxy compounds, mutagenicity, 50
- Baroreceptor reflexes, angiotensin influence, 433
- Berkowitz, Barry. *See* Spector *et al.*, 281
- Biguanides, lipolysis inhibitor, 93
- Bile, N-hydroxylated metabolites in, 19
- Blood  
 ferrihemoglobin, concentration, 21, 22  
 hemoglobin concentration in, 23  
 N-hydroxy derivatives, concentration, 21, 22  
 N-hydroxylated metabolites in, 19  
 nitroso compounds concentration, 21, 22
- Blood flow, spleen, 378
- Bloom, Floyd E., H. James Wedner, and Charles W. Parker, The use of antibodies to study cell structure and metabolism, 343
- Brain  
 angiotensin presence, 419  
 renin-angiotensin system, 421
- Braunwald, Eugene. *See* Higgins *et al.*, 119
- Bresnick, Edward, Report on the discussion of the third session (symposium), 315
- Butler, Vincent P., Jr., John F. Watson, Donald H. Schmidt, Jerry D. Gardner, William J. Mandel, and C. Lynn Skelton, Reversal of the pharmacological and toxic effects of cardiac glycosides by specific antibodies, 239
- Calabresi, Paul, Report on the discussion of the fourth session (symposium), 359
- Carbamylcholine chloride, effect on accumulation of cyclic AMP by myocardium, 127
- Carboxylic acids, cyclic  
 effect on  
 cyclic AMP, 86  
 lipolysis, 86
- Cardiac cholinoreceptive sites, activation, 124
- Cardiac glycosides, activity in fat cells, 95
- Cardiovascular reflexes  
 baroreceptor hypertension, 145  
 baroreceptor reflex, 144  
 chemoreceptor reflex, 146  
 cholinergic participation, 144
- Catecholamine  
 adenylate cyclase activation, 77, 78  
 beta-adrenergic blockers of adenylate cyclase activation, 78  
 cardiac stores, release, 122  
 directly acting, 384  
 indirectly acting, 391  
 lipase activation, 104  
 lipolysis activation, 70  
 lipolysis stimulation by, 72  
 lipolytic action, 73
- Central nervous system  
 angiotensin  
 adrenergic effects, 441  
 cholinergic effects, 441  
 macromolecular effects, 441  
 angiotension effects, 415
- Cerebrospinal fluid  
 angiotensin administration, effects (table), 429  
 angiotensin effects, 423
- Chloroquine effect on lipolysis, 95
- Chlorophenoxyisobutyrate, effect on fatty acid release, 96
- Cholinergic drugs, actions on splenic smooth muscle, 396
- Cocaine, effects on lipolysis, 97
- Coprophyagy, effect on gastrointestinal microflora, 456
- Coronary circulation, parasympathetic influences, 142
- Coronary vascular resistance  
 parasympathetic influences, 142  
 direct effects, 143  
 indirect effects, 142
- Daniels-Severs, Anne E. *See* Severs and Daniels-Severs, 415
- Davies, B. N. and P. G. Withrington, The actions of drugs on the smooth muscle of the capsule and blood vessels of the spleen, 373
- Dealkylation  
 N-alkyl compounds, 477  
 O-alkyl compounds, 475  
 alkyl derivatives, 478
- Deamination, gastrointestinal microflora, 480

- Decarboxylation, amino acids, 472
- Dehalogenation, gastrointestinal microorganisms, 478
- Dehydroxylation  
 C-hydroxyl compounds, 468  
 N-hydroxyl compounds, 472
- Deoxyribonucleic acids  
 N-hydroxy compounds and derivatives, reactions with, 42  
 N-hydroxy compounds, mutagenicity, 50  
 N-hydroxy compounds reaction with, 43
- Desipramine, effects on lipolysis, 97
- Diethylchelonate, effects on lipolysis, 97
- Dihydroergotamine  
 effect on cyclic AMP, 84  
 effect on lipolysis, 84
- Dinitrophenol, effect on lipolysis, 89
- Drug action  
 adipose tissue, 67  
 biochemical aspects, 67
- Drug metabolism, implications by gastrointestinal microorganisms, 507
- Dyrenfurth, I. *See* Vande Wiele and Dyrenfurth, 189
- Enterohepatic circulation, role of intestinal microorganisms, 506
- Ephedrine effects on splenic smooth muscle, 392
- Erlanger, Bernard F., Principles and methods for the preparation of drug protein conjugates for immunological studies, 271
- Esterification, gastrointestinal microorganisms, 499
- Esters, hydrolysis, 465
- O-Esters, formation, 31
- Ethylene diamine tetraacetate, lipase activation, 104
- Fain, John N., Biochemical aspects of drug and hormone action on adipose tissue, 67
- Fat cells  
 adrenergic receptors, 70  
 ATPase activity, 95  
 cardiac glycosides activity, 95  
 cyclic nucleotide effects, 81
- Fatty acids, chlorophenoxyisobutyrate effect on release of, 96
- Fenfluramine, effects on lipolysis, 98
- Ferrihemoglobin, concentration in blood, 21, 22
- Flavonoid glycosides hydrolysis, 460
- N-2-Florenylacetamide  
 biliary excretion (table), 12  
 N-hydroxylation in several species (table), 13  
 sodium sulfate effect on hepatocarcinogenesis (table), 33  
 urinary excretion (table), 12, 14
- Fluoride, glycolysis inhibitors, 94
- Flynn, Edward J. *See* Spector *et al.*, 281
- Franklin, Edward C., Report on the discussion of the second session (symposium), 269
- Gardner, Jerry D. *See* Butler *et al.*, 239
- Gastrointestinal metabolism  
 age, effects, 503  
 diet effects, 502  
 enzyme inhibition, 505  
 factors affecting, 501  
 foreign compounds, 501  
 membrane permeability characteristics, 505  
 metabolic adaptation, 504  
 physico-chemical properties, alterations, 505  
 species variation, 501
- Gastrointestinal microflora  
 acetylation, 499  
 aromatization, 497  
 coprophagy effects, 456  
 esterification, 499  
 influence of  
 age, 457  
 diet, 455  
 disease, 457  
 foreign compounds, 457  
 metabolic reactions, 458  
 nature of, 453  
 nitrosamine formation, 498  
 reduction of  
 alcohols, 496  
 aldehydes, 496  
 arsonic acids, 497  
 azo groups, 492  
 double bonds, 488  
 ketones, 486  
 N-oxides, 497  
 starvation effects, 456  
 typical representatives of (table), 454  
 toxicological implications, examples of reactions (table), 510  
 variations among different animal species, 455
- Gastrointestinal microorganisms. *See also* Gastrointestinal microflora  
 biliary metabolites, metabolism, (table), 508  
 dealkylation, 475  
 decarboxylation, 472  
 dehalogenation, 478  
 dehydroxylation, 468  
 distribution, 453  
 drug metabolism, implications, 507  
 enterohepatic circulation of compounds, role in, 506  
 heterocyclic ring fission, 480  
 metabolism of foreign compounds, 451  
 pharmacological significance, 509  
 reduction of nitro groups, 490  
 toxicological significance, 511
- Gavin, J. R., III. *See* Gorden *et al.*, 179
- Glick, Seymour M., Report on the discussion of the first session (symposium), 209

- Glucocorticoids, RNA and protein synthesis and lipolytic action, 101
- Glucose uptake, parasympathetic agents, 101
- Glucose metabolism  
 hemagglutinins, 108  
 inhibiting drugs, 108  
 metal ions, 107  
 neuraminidases, 106  
 phospholipases, 106  
 plasma factors, 106  
 polyamines, 108  
 polyene antibiotics, 108  
 proteases, 106  
 saponins, 108  
 stimulating agents, 105  
 thiols, 107
- Glucuronic acid conjugates, formation, 29
- Glucuronides, hydrolysis, 458
- Glycogen, N-hydroxy compounds and derivatives, reaction with, 46
- Glycosides, cardiac. *See* Cardiac glycosides
- Glycosides, hydrolysis, 458
- Glycolysis  
 fluoride effects, 94  
 inhibitors, 94  
 iodoacetate effects, 94
- Gorden, P., J. R. Gavin, III, C. R. Kahn, J. A. Archer, M. Lesniak, C. Hendricks, D. M. Neville, Jr., and J. Roth, Application of radioreceptor assay to circulating insulin, growth hormone, and to their tissue receptors in animals and man, 179
- Growth hormone  
 lipolysis activation, 103  
 norepinephrine-sensitive adenylate cyclase activity in fat cell ghosts after incubation of fat cells with growth hormone (table), 102  
 RNA and protein synthesis in lipolytic action, 101
- Haber, Edgar, The role of antibodies and physiological receptors in cardiovascular diagnosis, therapy, and research, 215  
*See* Smith and Haber, 219
- Heart  
 atrial frequency after addition of cholinergic agents, 129  
 cholinoreceptive sites, activation, 124, 125  
 cyclic AMP regulation, 126  
 myocardial membrane permeability, alteration, 125  
 parasympathetic control, 119
- Heart conduction system  
 arrhythmias, genesis, 141  
 atrioventricular node, 140  
 parasympathetic influence, 137  
 Purkinje system and ventricular pacemaker cells, 141  
 sinoatrial node and atrial pacemaker, 140
- Heart rate  
 adrenergic intervention, 139  
 asphyxia, response to, 129  
 cholinergic intervention, 139  
 isoproterenol, response to, 129  
 paradoxical tachycardia, 137  
 parasympathetic influence, 137  
 vagal activity timing, 139  
 vagal nerve stimulation, 138
- Heart rhythm, parasympathetic influence, 137
- Hemagglutinins, glucose metabolism, 108
- Hemoglobin concentration in blood, 23
- Hendricks, C. *See* Gorden *et al.*, 179
- Hepatocarcinogenesis; sodium sulfate effect on inhibition (table), 33
- Heterocyclic ring fission, gastrointestinal microorganisms, 480
- Higgins, Charles B., Stephen F. Vatner, and Eugene Braunwald, Parasympathetic control of the heart, 119
- Histamine actions on splenic smooth muscle, 403
- Hormone action  
 adipose tissue, 67  
 biochemical aspects, 67
- Hydration  
 angiotensin effects, 434  
 significance of angiotensin effects, 439
- Hydroxamic acids  
 biochemical formation, 1  
 pathological properties, 1  
 pharmacological properties, 1  
 toxicological properties, 1
- N-Hydroxy acetamides, deacylation, 33
- N-Hydroxy amides, acetanilide metabolite interference, 32
- N-Hydroxy compounds  
 aliphatic, 2  
 analysis, 6  
 aromatic, 2  
 biochemical reactions, 29  
 carcinogenicity, 46  
 chemical synthesis, 3  
 isomerization, 36  
 methemoglobin production, 22  
 mutagenicity, 49  
 reactions, 3  
 reaction with  
 cellular constituents, 37  
 cellular macromolecules, 37  
 deoxyribonucleic acids, 42  
 glycogen, 46  
 polyribonucleotides, 41  
 protein, 38  
 ribonucleic acid, 40  
 tissue, 37  
 reduction, 35  
 structures, 3

- N-Hydroxy derivatives**  
 aromatic amines, 3  
 bile, metabolites in, 19  
 biochemical oxidation-N-hydroxylation, 8  
 biochemical reduction, 27  
 blood, concentration in, 21, 22  
 blood, metabolites in, 19  
 natural products containing, 2  
 reaction with  
   cellular constituents, 37  
   cellular macromolecules, 37  
   deoxyribonucleic acids, 42  
   glycogen, 46  
   polyribonucleotides, 41  
   proteins, 38  
   ribonucleic acid, 40  
 tissue, 37  
 urinary excretion, 10, 14
- 5-Hydroxy-2-fluorenylacetylamide**, urinary excretion of, 18
- 7-Hydroxy-2-fluorenylacetylamide**, urinary excretion of, 18
- N-Hydroxy-2-fluorenylacetylamide**  
 biliary excretion (table), 12  
 urinary excretion (table), 12
- N-Hydroxy-N-2-fluorenylacetylamide**  
 dehydroxylation, 16  
 sodium sulfate effect on hepatocarcinogenesis (table), 33  
 urinary excretion of, 18
- Hydroxylamines**  
 aliphatic, 3  
 aromatic, 4  
 biochemical formation, 1  
 pathological properties, 1  
 pharmacological properties, 1  
 toxicological properties, 1  
 urinary excretion of N-oxidation products, 11
- N-Hydroxylated metabolites**  
 urine  
   evidence in, 8  
   modifying factors, 13
- N-Hydroxylation**  
*in vitro*, 26  
   modifiers, 26  
   species, 26  
   stability, 26  
   structure requirements, 27  
   tissue, 26  
*in vivo*, 8
- C-Hydroxyl compounds**  
 dehydroxylation, 468
- 5-Hydroxytryptamine** (*see also* Serotonin), actions on splenic smooth muscle, 405
- Hypothalamus**, angiotensin injections, 432
- Imidazoles**  
 effect on  
   cyclic AMP, 85  
   lipolysis, 85
- Imipramine, effects on lipolysis, 97
- Iodoacetate, glycolysis inhibitors, 94
- Ionophorous antibiotics effect on lipolysis, 90
- Isoprenaline effects on splenic smooth muscle, 391
- Kahn, C. R. *See* Gorden *et al.*, 179
- Ketones, reduction by gastrointestinal microorganisms, 496
- Kinens, actions on splenic smooth muscle, 402
- La Du, Bert N., Introduction (symposium), 157
- Lefkowitz, Robert J., Isolated *beta*-adrenergic binding sites: a potential assay vehicle for catecholamines, 259
- Lesniak, M. *See* Gorden *et al.*, 179
- Levine, Lawrence, Antibodies to pharmacologically active molecules; specificities and some applications of antiprostaglandins, 293
- Lindenbaum, John, Bioavailability of digoxin tablets, 229
- Lipase**  
 activation by  
   catecholamines, 104  
   EDTA, 104  
   lipoprotein, 104
- Lipase activity, cell-free system, 102
- Lipolysis**  
 activation by  
   catecholamine, 70  
   growth hormone, 103
- effects of  
 adenosine, 81  
 amytal, 89  
 anorexigenic drugs, 98  
 antidepressants, 97  
 antimalarials, 95  
 antimycin A, 89  
 aspirin-like drugs, 87  
 cocaine, 97  
 cyclic AMP, 81  
 cyclic carboxylic acids, 86  
 diethylchelidonate, 97  
 dihydroergotamine, 84  
 imidazoles, 85  
 ionophorous antibiotics, 90  
 oligomycin, 89  
 piericidin A, 89  
 prostaglandins, 87  
 protein synthesis inhibitors, 100  
 RNA inhibitors, 100  
 rotenone, 89  
 serotonin, 99  
 thyroid hormone, 99
- biguanides, as inhibitors, 93  
 catecholamine stimulation of, 72  
 dinitrophenol, 89

- Lipolysis—*continued*  
 drugs affecting  
   accumulation, 83  
   action, 83  
 glucocorticoids, 101  
 growth hormone, 101  
 inhibition in fat cells, 95  
 naphthoquinones, 90  
 nucleoside inhibitors, 91  
 oxidative metabolism, inhibitors and uncouplers, 89  
 parasympathetic agents, 101  
 sulfhydryl inhibitors, 96  
 sulfonylurea inhibitors, 93  
 Lipolytic agents, cyclic AMP accumulation, 79  
 Lipoprotein lipase, 104  
 Liver carcinogenesis, restoration by dietary sulfate (table), 34
- Mandel, William J. *See* Butler *et al.*, 239  
 Medulla, angiotensin injections, 432  
 Metabolism  
   gastrointestinal microorganisms, 451  
   oxidative  
     inhibitors, 89  
     uncouplers, 89  
 Metal ions, glucose metabolism, 107  
 Methemoglobin production, N-hydroxy compounds, 22  
 Methionine reaction mechanism with N-hydroxy derivatives, 38  
 Methyl xanthines  
   effect on  
     cyclic AMP, 83  
     lipolysis, 83  
 Midbrain angiotensin injections, 423  
 Myocardial contractility, parasympathetic influences, 130
- Naphthoquinones effect on lipolysis, 90  
 Nerve stimulation effects on spleen, 380  
 Neuraminidases, glucose metabolism, 106  
 Neville, D. M., Jr. *See* Gordon *et al.*, 179  
 Nitrates, hydrolysis of, 468  
 Nitro groups reduction by gastrointestinal microorganisms, 490  
 Nitrosamine formation by gastrointestinal microorganisms, 498  
 Nitroso compounds concentration in blood, 21, 22  
 Noradrenaline action on splenic smooth muscle, 384, 386  
 Norepinephrine in endogenous brain, 442  
 Nucleosides  
   inhibitors of  
     cyclic AMP accumulation, 91  
     lipolysis, 91  
 Nucleotide, cyclic, effects on fat cells, 81
- Oligomycin effect on lipolysis, 89
- N-Oxides, heterocyclic  
   formation of, 28  
   reactions, 28  
 N-Oxides reduction by gastrointestinal microorganisms, 497  
 N-Oxy compounds, structures, 3  
 N-Oxy derivatives  
   allergic reactions, 46  
   immunological reactions, 46  
 Oxytocin actions on splenic smooth muscle, 400
- Papaverine  
   effect of cyclic AMP, 83  
   effect on lipolysis, 83  
 Parasympathetic influences, modulation of, 127  
 Parasympathetic nerve stimulation, spleen, 383  
 Parasympathetic-sympathetic interactions, 127  
 Pargyline effect on lipolysis, 98  
 Parker, Charles W., The immunotherapy of cancer, 325  
 Parker, Charles W. *See* Bloom *et al.*, 343  
 Peptides  
   hypertensive, effects on splenic smooth muscle, 401  
   hypotensive, actions on splenic smooth muscle, 402  
   neurohypophyseal peptides action on spleen, 399  
 Peskar, Bernard. *See* Spector *et al.*, 281  
 Phosphodiesterase inhibitors  
   effect on  
     cyclic AMP, 83  
     lipolysis, 83  
 Phospholipases, glucose metabolism, 106  
 Piericidin A effect on lipase activity, 89  
 Pituitary, effects of angiotensin, 438  
 Polyamines, glucose metabolism, 108  
 Polyene antibiotics, glucose metabolism, 108  
 Polypeptides effect on splenic smooth muscle, 399  
 Polyribonucleotides, N-hydroxy compounds and derivatives, reactions with, 41  
 Poulsen, Knud, Measurements of renin-angiotensin-aldosterone, 249  
 Primaquine effect on lipolysis, 95  
 Prostaglandins  
   action on splenic smooth muscle, 405  
   effect on  
     cyclic AMP, 87  
     lipolysis, 87  
 Proteases, glucose metabolism, 106  
 Protein, N-hydroxy compounds and derivatives, reactions with, 38  
 Protein synthesis  
   glucocorticoids lipolytic activity, 101  
   growth hormone lipolytic action, 101  
   inhibitors, 100  
 Protriptyline effects on lipolysis, 97
- Quinacrine effect on lipolysis, 96

- Quinidine effect on lipolysis, 96  
 Quinine effect on fatty acid release, 95
- Renin-angiotensin system, components in brain, 421
- Ribonucleic acid  
 N-hydroxy compounds and derivatives, reactions with, 40  
 inhibitors, 100
- Ribonucleic acid synthesis  
 glucocorticoids lipolytic action, 101  
 growth hormone lipolytic action, 101
- Rotenone effect on lipase activity, 89
- Roth, J. See Gorden *et al.*, 179
- Saponins, glucose metabolism, 108
- Scheline, Ronald R., Metabolism of foreign compounds by gastrointestinal microorganisms, 451
- Schmidt, Donald H. See Butler *et al.*, 239
- Serotonin effect on lipolysis, 99
- Severs, Walter B. and Anne E. Daniels-Severs, Effects of angiotensin on the central nervous system, 415
- Siskind, Gregory W., Manipulation of the immune response, 319
- Skelton, C. Lynn. See Butler *et al.*, 239
- Smith, Thomas W. and Edgar Haber, Clinical value of the radioimmunoassay of the digitalis glycosides, 219
- Spector, Sydney, Barry Berkowitz, Edward J. Flynn, and Bernard Peskar, Antibodies to morphine, barbiturates, and serotonin, 281
- Spleen  
 actions of  
 histamine, 403  
 kinens, 402  
 vasoactive amines, 403  
 adrenaline actions  
 capsular smooth muscle, 384  
 vascular smooth muscle, 386  
 alpha blocking agents, 393  
 amphetamine, 393  
 angiotensin effects, 401  
 beta blocking agents, 395  
 blood flow, 378  
 different species (table), 379  
 blood vessels, 373  
 intermediate circulation and, 376  
 drug actions, 373  
 catecholamines  
 directly acting, 384  
*in vitro* preparations, 388  
 transillumination studies, 389  
 indirectly acting  
 tyramine, 391  
 cholinergic drugs, actions, 396  
 ephedrine, 392  
 histology, 374  
 hypertensive peptides, 401  
 hypotensive peptides, 402  
 5-hydroxytryptamine, actions, 405  
 innervation, 377  
*in situ* preparations, 378  
 investigation methods, 378  
 isolated or spleen strips, 380  
 isolated perfused, 379  
 isoprenaline  
*in vitro* observations, 390  
*in vivo* observations, 390  
 lymphatic supply, 377  
 nerve stimulation, effects, 380  
 neurohypophyseal peptide action, 399  
 neurohypophyseal peptides, 399  
 noradrenaline action on capsular smooth muscle, 384  
 noradrenaline actions on vascular smooth muscle, 386  
 oxytocin effects, 400  
 parasympathetic nerve stimulation, 383  
 polypeptides actions, 399  
 prostaglandins actions, 405  
 smooth muscle, 373  
 distribution, 374  
 drug actions, 373  
 splenic weight and body weight, relationship in different species, (table), 375  
 sympathetic nerve stimulation, 381  
 tyramine, 391  
 vasopressin effects, 400  
 weight, 374  
 Starvation effect on gastrointestinal microflora, 456
- Steiner, Alton L., Radioimmunoassay for the cyclic nucleotides, 309
- Sulfamates, hydrolysis of, 467
- Sulfate esters, hydrolysis of, 461
- Sulfhydryl inhibitors, lipolysis of, 96
- Sulfonylureas, lipolysis inhibitor, 93
- Sulfuric acid conjugates, formation, 31
- Sympathetic nerve activity, angiotensin influence, 433
- Sympathetic nerve stimulation of spleen, 381
- Tachycardia, paradoxical, 137
- Tertiary amine  
 formation, 28  
 reactions, 28
- Thiols, glucose metabolism of, 107
- Thyroid hormones effect on lipolysis, 99
- Tolbutamide effects on cyclic AMP and ATP, 93
- Tranylecypromine effect on lipolysis, 98
- Triglyceride lipase, hormone-sensitive, 102
- Tyramine  
 effect on  
 lipolysis, 97  
 splenic smooth muscle, 391

- Urethan, N-hydroxylation of, 18  
Urine, N-hydroxylated metabolites in, 8
- Vagal nerve fibers, terminal distribution, 122  
Vagal stimulation  
  effects on  
    atrium, 130  
    ventricle, 132
- Valinomycin  
  effects on  
    cyclic AMP accumulation, 81  
    lipolysis, 81
- Vande Wiele, R. L. and I. Dyrenfurth, Gonadotropin-steroid interrelationships, 189
- Vasoactive amines action on splenic smooth muscle, 403
- Vasopressin effect on splenic smooth muscle, 400
- Vatner, Stephen F. *See* Higgins *et al.*, 119
- Ventricle  
  effects of  
    acetylcholine infusion, 135  
    vagal stimulation, 132  
  parasympathetic innervation, 120  
    histological evidence, 120  
    physiological evidence, 121
- Watson, John F. *See* Butler *et al.*, 239
- Wedner, H. James. *See* Bloom *et al.*, 343
- Weisburger, Elizabeth K. *See* Weisburger and Weisburger, 1
- Weisburger, John H. and Elizabeth K. Weisburger, Biochemical formation and pharmacological, toxicological, and pathological properties of hydroxylamines and hydroxamic acids, 1
- Withrington, P. G. *See* Davies and Withrington, 373
- Yalow, Rosalyn S., Dedication (symposium), 159
- Yalow, Rosalyn S., Radioimmunoassay methodology: application to problems of heterogeneity of peptide hormones, 161